Cite

HARVARD Citation

    Oliva-Damaso, N. et al. (2021). Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO. Kidney360. 2 (11), pp. 1696-1698. [Online]. 
  
Back to record